Browsing Harvard Law School by Keyword "insider trading"
Now showing items 1-2 of 2
-
Placebo or Panacea: The FDA's Rejection of ImClone's Erbitux Licensing Application
(2003)This paper draws upon the media reports, congressional hearing testimony, and company press releases to recount events surrounding the FDA’s refusal to issue a license to ImClone’s ... -
Share Repurchases, Equity Issuances, and the Optimal Design of Executive Pay
(2011)This Article identifies a cost to public investors of tying executive pay to the future value of a firm’s stock - even its long-term value. In particular, such an arrangement can incentivize executives to engage in share ...